58328-39-5 Usage
Description
5-BROMO-2,3-DIHYDRO-1,4-BENZODIOXANE is an organic compound that serves as a reagent in the synthesis of various pharmaceutical compounds. It is characterized by the presence of a bromo group attached to a benzodioxane ring, which provides unique chemical properties and reactivity.
Used in Pharmaceutical Industry:
5-BROMO-2,3-DIHYDRO-1,4-BENZODIOXANE is used as a reagent for the preparation of a kinase M2 activator, which is a potential therapeutic agent for cancer treatment. Its unique structure allows for the development of targeted therapies that can selectively activate or inhibit specific kinases, leading to the modulation of cellular signaling pathways and the inhibition of tumor growth and progression.
Check Digit Verification of cas no
The CAS Registry Mumber 58328-39-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,3,2 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 58328-39:
(7*5)+(6*8)+(5*3)+(4*2)+(3*8)+(2*3)+(1*9)=145
145 % 10 = 5
So 58328-39-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H7BrO2/c9-6-2-1-3-7-8(6)11-5-4-10-7/h1-3H,4-5H2
58328-39-5Relevant articles and documents
COMBINATION PRODUCT FOR THE TREATMENT OF CANCEROUS DISEASES
-
Page/Page column 138, (2021/12/31)
The present invention relates to a product for combination therapies useful for the treatment of cancer diseases. In particular, the invention relates to the combination of an anti-PD-Ll antibody and an MCT4 inhibitor of Formula (I). The therapeutic combination may be utilized for the use in treating a subject having a cancer disease that tests positive for PD-L1 and/or MCT4 expression.
Aromatic heterocyclic derivatives as enzyme inhibitors
-
Page column 123, (2010/02/04)
The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
